UpDoc Debuts First FDA-Cleared Patient-Facing Clinical LLM

For healthcare ML teams, this is the clearest signal yet that patient-facing large language models can clear FDA review when the task is narrowly scoped. On June 25, 2026, UpDoc publicly debuted what it calls the first FDA-cleared agentic clinical AI platform to use patient-facing LLMs; FDA's 510(k) database lists the underlying clearance, K253281, as posted December 23, 2025. Reporting identifies the device as UpDoc V1.0, a prescription software product for insulin management in adults with type 2 diabetes, where patients receive insulin titration guidance by voice or text. It was cleared against a drug-dose-calculator predicate and supported by a Stanford titration trial, and is designed to support clinicians with EHR integration rather than replace them. UpDoc reports $18 million in seed funding and early deployments at Cleveland Clinic, AHN, and UCSF.